Under the agreement, TS Pharma will commercialize the product in Antigua, Aruba, Bahamas, Barbados, Belize, Bermuda, Cayman Islands, Costa Rica, Curacao, , Dominican Republic, Guatemala, Haiti, Honduras, Jamaica, Netherland Antilles El Salvador, Panama, and Trinidad & Tobago.
Onko-Sure detects and/or monitors 15 different types of cancers by using a simple non-invasive blood test method.
Radient chairman and CEO Douglas MacLellan said with this agreement, they are making Onko-Sure available in additional new markets.